Wwox inactivation enhances mammary tumorigenesis

Oncogene

Volumn 30, Issue 36, 2011, Pages 3900-3906

  Abdeen, S K ^a   Salah, Z ^a   Maly, B ^b   Smith, Y ^a   Tufail, R ^c   Abu Odeh, M ^a   Zanesi, N ^d   Croce, C M ^d   Nawaz, Z ^c   Aqeilan, R I ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

breast cancer; triple negative; tumor suppressor; WW domains; WWOX

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER GROWTH; CANCER RISK; CELL DEATH; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DETERMINATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC PREDISPOSITION; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UPREGULATION; WWOX GENE;

MURINAE; MUS;

EID: 85027916646     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.115     Document Type: Article

References (23)

1. Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A et al. (2007a). Association of Wwox with ErbB4 in breast cancer. Cancer Res 67: 9330-9336. (Pubitemid 47535922)
2. Aqeilan RI, Hagan JP, Aqeilan HA, Pichiorri F, Fong LY, Croce CM. (2007b). Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res 67: 5606-5610. (Pubitemid 46984989)
3. Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y et al. (2007c). Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104: 3949-3954. (Pubitemid 47181559)
4. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. (2000). WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140-2145. (Pubitemid 30225175)
5. Del Mare S, Salah Z, Aqeilan RI. (2009). WWOX: its genomics, partners, and functions. J Cell Biochem 108: 737-745.
6. Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, Slingerland J et al. (2006). WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol 20: 2343-2354. (Pubitemid 44496405)
7. Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. (2005). Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 146: 1707-1712. (Pubitemid 40396878)
8. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S et al. (2009). Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115: 899-908.
9. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P et al. (2005). Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55: 471-478. (Pubitemid 41097847)
10. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L et al. (2004). From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 64: 7748-7755. (Pubitemid 39446906)
11. Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K. (2007). Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13: 268-274. (Pubitemid 46121879)
12. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
13. Klein A, Wessel R, Graessmann M, Jurgens M, Petersen I, Schmutzler R et al. (2007). Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. Int J Cancer 121: 683-688. (Pubitemid 46986504)
14. Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH et al. (2010). Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res 70: 5577-5586.
15. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE et al. (2005). Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 89: 99-105. (Pubitemid 40249042)
16. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Molecular portraits of human breast tumours. Nature 406: 747-752.
17. Polyak K. (2007). Breast cancer: origins and evolution. J Clin Invest 117: 3155-3163. (Pubitemid 350096968)
18. Radmacher MD, Simon R. (2000). Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92: 48-53. (Pubitemid 30082228)
19. Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK et al. (2000). Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 9: 1651-1663. (Pubitemid 30427002)
20. Salah Z, Aqeilan R, Huebner K. (2010). WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol 6: 249-259.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874. (Pubitemid 32878711)
22. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. (1995). Characterization of a novel protein-binding module - the WW domain. FEBS Lett 369: 67-71.
23. Turner BC, Ottey M, Zimonjic DB, Potoczek M, Hauck WW, Pequignot E et al. (2002). The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 62: 4054-4060. (Pubitemid 34791074)